The enrollment criteria in our study were not restrictive as mentioned in study population

above. Accordingly the difference in enrollment w.r.t. age, severity of AGE and month of enrollment across sites/regions might have led to wide variation in proportion of RVGE across regions. The overall study duration was less than 1 year; therefore annual patterns MEK inhibitor in the rotavirus strains could not be ascertained. Despite these limits the study has obvious strengths: we used uniform protocol across the sites and well-established central laboratory support for RV diagnosis and typing; we used diary cards and questionnaires to understand the entire spectrum of the disease from its onset and also economic and psychological impact associated with it. We focused the study on RGVE disease in urban private clinics which has previously been under researched. To our knowledge this is the first well designed multicentric study to provide data on RVGE burden in urban private OPD setting among children with AGE in India. We conclude that a high proportion of rotavirus among AGE cases ABT199 attend pediatric outpatient clinics in urban areas of India. This is associated with substantial economic and psychological burden caused by RVGE. The results support that

there is definite need of well tolerated and effective rotavirus vaccine for all eligible children in India. All of the authors made contributions to the conception and design of this study analyses, acquisition of data or analysis and interpretation of data. They actively participated in drafting the article or revised it for important intellectual content. The report was critically reviewed and subsequently approved by each co-author. Gajanan S. Namjoshi and Sudhanshu Pandey are employees of MSD. Sudhir Babji is employee of Christian Medical College, Vellore and has no conflicts to declare. Dr. S.K. Lalwani, Dr. Apurba Ghosh, Dr. Monjori Mitra, Dr. Anupam Sachdeva, Dr. Sundaram Balasubramanian, Dr. Suhas Kulkarni, Dr. V.K. Goyal were investigators in study

and declare that they received investigator’s grant from MSD. The investigators aminophylline also declare that they have received honoraria and support from MSD and different pharmaceutical companies for their engagement in sponsored promotional and educational activities by the companies. This study was sponsored and funded by MSD Pharmaceuticals Private Limited, Mumbai, India (MSD) (A subsidiary of Merck & Co. Inc., Whitehouse Station, NJ, U.S.A.) which markets RotaTeq® (Rotavirus vaccine, live, oral, pentavalent). The authors thank Dr. Pawan Sharma, Dr. Erukulla Arjun, Dr. K. Siva Rama Prasad, Dr. Ravindra Kumar, Dr. Sonali Palkar for their contribution as investigators in the study. Authors thank The Wellcome Trust Research Laboratory, Department of Gastrointestinal Modulators Sciences, Christian Medical College, Vellore, India for its laboratory support.